# Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock

> **NCT06556472** · NA · NOT_YET_RECRUITING · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 126 (estimated)

## Conditions studied

- Acute on Chronic Liver Failure

## Interventions

- **DRUG:** Terlipressin
- **DRUG:** Norephrine

## Key facts

- **NCT ID:** NCT06556472
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-15
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2024-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06556472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06556472, "Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06556472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*